We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+10.42%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$2.14B
AUM Growth
+$26.3M
Cap. Flow
-$108M
Cap. Flow %
-5.04%
Top 10 Hldgs %
74.41%
Holding
40
New
1
Increased
15
Reduced
4
Closed
2

Top Buys

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$21.1M
2
EPZM
Epizyme, Inc
EPZM
+$13.7M
3
ABMD
Abiomed Inc
ABMD
+$4M
4
AIMT
Aimmune Therapeutics
AIMT
+$2.22M
5
INSM icon
Insmed
INSM
+$1.5M

Top Sells

Rank Stock Value
1
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$113M
2
CLVS
Clovis Oncology, Inc.
CLVS
+$34.6M
3
SAGE
Sage Therapeutics
SAGE
+$4.98M
4
UTHR icon
United Therapeutics
UTHR
+$2M
5
RIGL icon
Rigel Pharmaceuticals
RIGL
+$1.09M

Sector Composition

Rank Sector Weight
1 Healthcare 94.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALIM
26
DELISTED
Alimera Sciences
ALIM
$4.19M 0.2%
200,920
– –
VIRX
27
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$3.14M 0.15%
33,214
– –
TLPH icon
28
Talphera
TLPH
$76.3M
$2.22M 0.1%
51,636
– –
DRNA
29
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$1.59M 0.07%
500,913
+19,394
+4% +$61.2K
CEMP
30
DELISTED
Cempra, Inc.
CEMP
$1.56M 0.07%
340,320
– –
CYTK icon
31
Cytokinetics
CYTK
$10.6B
$1.5M 0.07%
123,686
– –
ACGN
32
DELISTED
Aceragen Inc
ACGN
$1.06M 0.05%
4,537
– –
TRVN
33
DELISTED
Trevena, Inc.
TRVN
$785K 0.04%
546
– –
SPHS
34
DELISTED
Sophiris Bio, Inc.
SPHS
$543K 0.03%
247,000
– –
OCGN icon
35
Ocugen
OCGN
$465M
$542K 0.03%
5,049
– –
ZGNX
36
DELISTED
Zogenix, Inc.
ZGNX
$428K 0.02%
29,500
– –
ARCT icon
37
Arcturus Therapeutics
ARCT
$214M
$306K 0.01%
38,970
– –
SLNO
38
DELISTED
Soleno Therapeutics
SLNO
$212K 0.01%
5,650
– –
PGEN icon
39
Precigen
PGEN
$2.46B
– –
-41,900
Closed -$830K
ZLTQ
40
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
– –
-2,032,692
Closed -$113M
1
2

Similar funds

RRA
Round Rock Advisors Wilton, Connecticut $654M AUM 22.95% 1-Year Est. Return
AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
CG
CFO4Life Group Coppell, Texas $656M AUM 17.88% 1-Year Est. Return
GAMA
Graticule Asia Macro Advisors New York $649M AUM
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
RK
Rather & Kittrell Knoxville, Tennessee $648M AUM 14.68% 1-Year Est. Return

Palo Alto Investors's Q2 2017 Portfolio in Review

As of Q2 2017, Palo Alto Investors held 40 positions worth $2.14B, up 1.2% from $2.12B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Palo Alto Investors withdrew a net $108M in Q2 2017, closing 2 positions and reducing 4 holdings. Its most notable exit was ZELTIQ Aesthetics, Inc., an estimated $113M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 95% a quarter earlier.

Against the trend, Palo Alto Investors opened a new position in Immunomedics Inc worth $26.6M.

  • Palo Alto Investors's largest Q2 2017 buy was Immunomedics Inc: 3,010,466 shares worth $26.6M.
  • Palo Alto Investors added most to Epizyme, Inc in Q2 2017, an estimated $13.7M increase.
  • Palo Alto Investors's biggest Q2 2017 reduction was Clovis Oncology, Inc., cutting an estimated $34.6M.
  • Palo Alto Investors fully exited ZELTIQ Aesthetics, Inc. in Q2 2017, selling an estimated $113M.
  • Palo Alto Investors's ten largest holdings make up 74% of its $2.14B portfolio in Q2 2017.
  • Palo Alto Investors opened 1 new position and closed 2 in Q2 2017.
  • Palo Alto Investors's portfolio value rose 1.2% quarter-over-quarter to $2.14B.

Based on Palo Alto Investors's 13F filing for Q2 2017, filed 14 Aug 2017.